Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets. In the historic dot.com year 2000, he trained as a CEFA analyst in Frankfurt and has since then accompanied over 20 IPOs in Germany.
Until 2018, he held various positions at banks as an asset manager, capital market and macro expert as well as fundamental equity analyst. He is passionate about the energy, commodity and technology markets as well as the tactical and strategic asset allocation of liquid investment products. As an expert speaker at investment committee meetings of funds as well as at customer events, he can still describe the course of the 1987 crash, one of the major buying opportunities of the last 33 years on the stock market.
Today, he knows that the profit in shares is not necessarily the result of buying cheaply, but above all of avoiding mistakes and recognizing in good time when markets are ready to let air out. After all, in addition to basic fundamental analysis, investing in stocks is above all a phenomenon of global liquidity and this must be monitored regularly.
Commented by André Will-Laudien
Commented by André Will-Laudien on July 19th, 2023 | 08:00 CEST
Cannabis 3.0 - will profits be made now? Canopy and Tilray under pressure, Cantourage Group positioned superbly
For a few days now, a long-neglected stock market segment has been attracting attention again: the cannabis industry. The North American industry protagonists Canopy and Tilray have recently attracted some stock market turnover again, but skepticism remains high. For those investors who did not exit in time, they had to write off around 95% of their investment in the last 2 years, and experts suspect that the revaluation of the former high-flyers is not yet complete. We take a look at the nebulous scenery of hemp speculation.
Read
Commented by André Will-Laudien on July 18th, 2023 | 07:55 CEST
Hydrogen makes headlines: Plug Power, ThyssenKrupp Nucera, Desert Gold, Nikola - Huge price swings!
Gains of over 100% in a single day, such occurrences are rare on the NASDAQ. The stock in question is no stranger: Nikola Motors. Currently, it is mainly the investment commitments for hydrogen projects that are causing investor excitement. In the case of Nikola, it was certainly also a short squeeze, as over 100 million shares had been sold short in recent months. Last Friday, the stock initially surged another 50% on historical volume, but this gain dropped to just 0.3% by closing. High risks, but where are the opportunities?
Read
Commented by André Will-Laudien on July 17th, 2023 | 08:35 CEST
Breakout: 300% possible with hydrogen and silver! Nel and Plug Power set the pace, TUI and Defiance Silver in turnaround
The stock exchanges ignite one firework after another. While the German leading index DAX has been busy recovering all its losses from July last week, the NASDAQ has already set new records. High-tech companies are leading the way, especially those with AI fantasy. Here, rosy times are expected while the European industry continues to struggle, as demonstrated impressively by BASF's profit warning. In addition to a nice recovery rally in the hydrogen stocks, silver also made a proper move upwards. Here is an overview of the possible "breakouts".
Read
Commented by André Will-Laudien on July 13th, 2023 | 08:20 CEST
Batteries are the solution to the climate dispute! Varta and BASF explode, while BYD and Power Nickel step on the gas!
After months of losses, battery-related stocks are in high demand again. Varta and BASF are leading the way with up to 50% gains! Varta is delivering initial results from its restructuring efforts, reigniting investor enthusiasm. The China market leader in e-mobility, "Build Your Dreams" (BYD), has also made decent gains since its spring weakness. The Canadian company Power Nickel is preparing to supply the battery market with high-grade nickel. Which share should be preferred now?
Read
Commented by André Will-Laudien on July 12th, 2023 | 07:50 CEST
Prime Day at Amazon! Nvidia, Defense Metals, Infineon - No Artificial Intelligence without metals!
US Treasury Secretary Janet Yellen has concluded her four-day trip to China. The conclusion of the visit is quite positive on both sides, even if Yellen openly admits differences between the two world powers. Relations between Washington and Beijing have deteriorated significantly in recent years over trade and human rights issues, dealings with Taiwan, and a host of other issues. However, the supply situation of strategic raw materials remains an important issue. We examine buying opportunities in the high-tech sector.
Read
Commented by André Will-Laudien on July 11th, 2023 | 06:55 CEST
Hydrogen ahead of e-mobility! Nucera rises, Tesla falls - What are First Hydrogen, Nel and Plug Power doing?
The complete renewal of the energy landscape is gobbling up trillions. While the EU wants to spend at least EUR 300 billion over the next 10 years on e-mobility, wind and solar power, there are now already many private investors jumping on the bandwagon. Joe Biden's Inflation Act includes, in addition to some social issues, the energetic renewal of the superpower USA, which has been purely fossil-fuel driven for decades. In the hydrogen sector, the profitable H2 subsidiary ThyssenKrupp Nucera has ventured into the market. With a capitalization of EUR 2.7 billion, a clean start has been made. It will be interesting to see how strongly the parent company ThyssenKrupp can profit from the revaluation of its subsidiary. We analyze the opportunities in the volatile hydrogen sector.
Read
Commented by André Will-Laudien on July 5th, 2023 | 07:55 CEST
666% rally in 5 years - can Nucera do even more? BioNTech, BioNxt Solutions, and Plug Power could be the winners!
The story of the Mainz-based biotech company BioNTech has set a precedent over the last 5 years. With a remaining gain of 666%, it still ranks among the best performers on the German stock market, even after a 75% price decline. Such movements usually take place on the NASDAQ, where it is easy for highly innovative technology or biotech stocks to raise the necessary growth capital. But not every stock market story is so positive. We go on a pearl diver's journey.
Read
Commented by André Will-Laudien on July 4th, 2023 | 07:50 CEST
Nucera IPO boosts Greentech shares: Varta, Manuka Resources, BASF and ThyssenKrupp on the buy list
Many companies have set themselves the goal of contributing to offsetting man-made emissions and combating climate change. One proven means is gradual decarbonization, for example, in the energy-intensive heavy industry sector. The IPO of ThyssenKrupp's hydrogen subsidiary, Nucera, is important from this perspective because the newly raised funds will be used to advance green steel production. It is a German project that could set an international precedent. We take a deeper look into an emerging sector.
Read
Commented by André Will-Laudien on July 3rd, 2023 | 07:45 CEST
Forget the heating law - 100% turnaround opportunity possible with Deutsche Bank, Volkswagen, BYD and Cardiol Therapeutics
When the major indices perform, some stocks unfortunately fall by the wayside. This can be due to a lack of attractiveness or the impact of megatrends such as Artificial Intelligence or Digitalization. Deutsche Bank is well on track for 2023, Volkswagen's low valuation is bound to attract attention at some point, and biotech company Cardiol Therapeutics is poised for a big jump. We take a closer look.
Read
Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST
Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!
In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.
Read